Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Fineline Cube Jan 26, 2026
Company Legal / IP

Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France

Fineline Cube Jan 2, 2024

French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...

Company Legal / IP

J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products

Fineline Cube Jan 2, 2024

A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...

Policy / Regulatory

China’s CDE Releases Guidelines for CGT Clinical Trials Communication

Fineline Cube Jan 2, 2024

The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...

Policy / Regulatory

China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...

Policy / Regulatory

China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...

Company Deals

Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology

Fineline Cube Jan 2, 2024

Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...

Company Drug

Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment

Fineline Cube Jan 2, 2024

US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...

Company Deals

Roche Secures Diagnostics Deal with LumiraDx for $295M

Fineline Cube Jan 2, 2024

Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...

Company Deals

Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug

Fineline Cube Jan 2, 2024

vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...

Company Drug

Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study

Fineline Cube Jan 2, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment

Fineline Cube Jan 2, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials

Fineline Cube Jan 2, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Deals

CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million

Fineline Cube Jan 2, 2024

CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced...

Company Deals

Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment

Fineline Cube Jan 2, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate...

Company Deals

Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for USD 1.8 Billion

Fineline Cube Jan 2, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish pharmaceutical company, has announced the formation of an...

Company Deals

MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million

Fineline Cube Jan 2, 2024

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Medical Device

P-Cure Initiates Construction of Affordable Proton Therapy Center in China’s Shandong Province

Fineline Cube Jan 2, 2024

P-Cure, an Israeli company specializing in proton therapy, has commenced construction on a proton therapy...

Company Deals

Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC

Fineline Cube Jan 2, 2024

Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...

Company Deals

Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development

Fineline Cube Dec 29, 2023

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B...

Company Drug

Boan Biotech Secures FDA Orphan Drug Designations for Pancreatic Cancer Treatments

Fineline Cube Dec 29, 2023

China-based Boan Biotech (HKG: 6955) has announced that its novel antibody BA1105 and antibody-drug conjugate...

Posts pagination

1 … 370 371 372 … 614

Recent updates

  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
  • Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
  • MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
  • Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Medical Device

MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.